NIH grantees win 2015 Nobel Prize in chemistry
Prize awarded for mapping, at a molecular level, how cells repair damaged DNA and safeguard the genetic information.
The 2015 Nobel Prize in chemistry has been awarded to National Institutes of Health (NIH) grantees Paul Modrich, of the Howard Hughes Medical Institute and the Duke University School of Medicine, Durham, NC; and Aziz Sancar, of the University of North Carolina, Chapel Hill, NC, for having mapped, at a molecular level, how cells repair damaged DNA and safeguard the genetic information. They share the award with Tomas Lindahl, of the Francis Crick Institute and Clare Hall Laboratory, Hertfordshire, UK.
The Royal Swedish Academy of Sciences said their work on DNA repair "has provided fundamental knowledge of how a living cell functions".
Thousands of spontaneous changes to a cell's genome occur on a daily basis while radiation, free radicals and carcinogenic substances can also damage DNA. To keep the information in the genetic instruction book from degrading, a range of molecular systems monitor and repair DNA, in processes that the three award-winning scientists all helped map out.
"This basic understanding about cell function has led to the discovery of the causes of genetic conditions associated with cancer, and is being used to develop new cancer treatments,” said NIH Director Francis S. Collins. "NIH is proud to have supported this work."
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.